Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus
Annals of the Rheumatic Diseases · 2025
DOI: 10.1016/j.ard.2025.07.028 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Annals of the Rheumatic Diseases, 2025. Verfasst von Yakai Fu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; UMR_S INSERM 1109, Immunorhumatologie M…. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Interleukin-15, Killer Cells, Natural, Antigens, CD19. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Natural Science Foundation of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
OBJECTIVES: Given the efficacy of B-cell depletion therapy in systemic lupus erythematosus (SLE) treatment and the capacity of engineered natural killer (NK) cells in B-cell elimination, we explored the potential of genetically modified NK cells to target CD19 for the treatment of SLE. METHODS: Peripheral blood-derived NK cells were engineered with CAR.CD19/interleukin (IL)-15 (XB-19.15) or CAR.CD19 alone. In vitro assays tested cytotoxicity, proliferation (Ki-67), and cytokine release (IL-15/interferon-gamma [IFN-γ]] against CD19+ cells (Raji, Nalm6, SLE B-cell). In vivo models included Nalm6-luc xenografts, humanised CD34+ mice, and SLE peripheral blood mononuclear cells xenografts to assess efficacy, persistence, and safety. A phase 1 trial enrolled 3 patients with refractory SLE receiving XB-19.15 as a proof-of-concept study. RESULTS: XB-19.15 showed superior cytotoxicity, sustained IL-15 secretion, and enhanced proliferation in vitro. In the mouse model, XB-19.15 showed significant dose-dependent tumour regression of Nalm-6 and B-cell depletion of humanised mice with long-term persistence in various lymphoid organs. The total levels of hIgG and anti-dsDNA antibodies were decreased in XB-19.15-treated groups with deep clearance of B-cell and plasma cells of bone marrow and spleen in the SLE xenograft model, indicating potential attenuation of SLE. Three patients received XB-19.15 achieved improvement in disease activity and reset of B-cell repertoires without severe adverse events. CONCLUSIONS: XB-19.15 enables potent, durable B-cell depletion and immune resetting in SLE with off-the-shelf utility and favourable safety. Preclinical and early clinical data support further trials to optimise dosing and confirm long-term efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; UMR_S INSERM 1109, Immunorhumatologie Moléculaire, Strasbourg, France.
- R&D Department, Shanghai Simnova Biotechnology Co., Ltd., Shanghai, China.
- Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
- R&D Department, Simcere Zaiming, Inc., Boston, MA, USA.
- Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai,…
- Shanghai Immune Therapy Institute, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
Förderung
- Science and Technology Commission of Shanghai Municipality
- Natural Science Foundation of Shanghai Municipality
- National Natural Science Foundation of China
- Shanghai Hospital Development Center
Zitieren
APA
Fu, Y., Xu, Z., Wu, C., Gao, F., Huang, P., Jiang, F., Hu, C., Patsoukis, N., Wang, Y., Cui, Z., Wen, L., Li, P., Wang, C., Ye, S., Cao, Z., & Fu, Q. (2025). Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.07.028
Vancouver
Fu Y, Xu Z, Wu C, Gao F, Huang P, Jiang F, et al. Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2025. doi:10.1016/j.ard.2025.07.028
BibTeX
@article{Fu2025,
author = {Fu, Yakai and Xu, Zupeng and Wu, Chunmei and Gao, Fangjie and Huang, Pengyu and Jiang, Fuwei and Hu, Chuxuan and Patsoukis, Nick and Wang, Yiyang and Cui, Zejin and Wen, Limin and Li, Peiying and Wang, Chong and Ye, Shuang and Cao, Zhuoxiao and Fu, Qiong},
title = {Genetically modified CD19-targeting IL-15 secreting NK cells for the treatment of systemic lupus erythematosus},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
doi = {10.1016/j.ard.2025.07.028}
}
EUVIMED